NL300142I1 - Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine. - Google Patents
Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine.Info
- Publication number
- NL300142I1 NL300142I1 NL300142C NL300142C NL300142I1 NL 300142 I1 NL300142 I1 NL 300142I1 NL 300142 C NL300142 C NL 300142C NL 300142 C NL300142 C NL 300142C NL 300142 I1 NL300142 I1 NL 300142I1
- Authority
- NL
- Netherlands
- Prior art keywords
- cytotoxin
- expresses
- preparation
- cell line
- monoclonal antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL73883A IL73883A (en) | 1984-12-20 | 1984-12-20 | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
NL300142I1 true NL300142I1 (nl) | 2004-04-01 |
NL300142I2 NL300142I2 (nl) | 2005-08-01 |
Family
ID=11055557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL300142C NL300142I2 (nl) | 1984-12-20 | 2004-02-12 | Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6090923A (nl) |
EP (1) | EP0186833B2 (nl) |
JP (2) | JPS61191620A (nl) |
AU (1) | AU601144B2 (nl) |
CA (1) | CA1337518C (nl) |
DE (5) | DE122004000007I1 (nl) |
IL (1) | IL73883A (nl) |
NL (1) | NL300142I2 (nl) |
ZA (1) | ZA859757B (nl) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019385A (en) * | 1984-11-09 | 1991-05-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Novel lymphopine LK 2 and pharmaceutic compositions containing same |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
JP3155961B2 (ja) * | 1987-12-30 | 2001-04-16 | 煕 中島 | 抗ビリルビンモノクローナル抗体固定担体およびその製造方法 |
EP0409901A4 (en) * | 1988-04-15 | 1991-10-30 | Research Corporation Technologies, Inc | Lak cell cytotoxin |
IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
DK0585705T3 (da) * | 1992-08-28 | 1999-07-26 | Bayer Ag | Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis |
ATE237808T1 (de) * | 1992-10-21 | 2003-05-15 | Stefan Miltenyi | Direkte auswahl von zellen durch ein aussheidungsprodukt |
US7166423B1 (en) | 1992-10-21 | 2007-01-23 | Miltenyi Biotec Gmbh | Direct selection of cells by secretion product |
IL114615A0 (en) | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
IL126024A0 (en) * | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
IL178921A0 (en) * | 1998-12-24 | 2007-03-08 | Yeda Res & Dev | Caspase-8 interacting proteins |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20050002900A1 (en) * | 2001-11-06 | 2005-01-06 | Grace Wong | Method of treating estrogen responsive breast cancer |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
WO2004019861A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
US20040247588A1 (en) * | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
DK2447375T3 (da) | 2004-03-31 | 2019-07-29 | Massachusetts Gen Hospital | Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
NZ610566A (en) | 2006-04-05 | 2014-09-26 | Abbvie Biotechnology Ltd | Antibody purification |
WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
EA018101B1 (ru) | 2007-05-11 | 2013-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы лечения кожных язв |
ES2540933T3 (es) | 2007-05-11 | 2015-07-14 | Thomas Jefferson University | Métodos de tratamiento y prevención de enfermedades y trastornos neurodegenerativos |
CN101679511A (zh) * | 2007-06-06 | 2010-03-24 | 杜门蒂斯有限公司 | 多肽、抗体可变域和拮抗剂 |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
JP5570998B2 (ja) | 2007-12-31 | 2014-08-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | TNFαに対する抗体 |
CN104188911A (zh) | 2008-01-15 | 2014-12-10 | Abbvie德国有限责任两合公司 | 粉末状蛋白质组合物及其制备方法 |
EP2228652A1 (en) | 2009-03-11 | 2010-09-15 | Medizinische Universität Wien | Improvement of tumour treatment |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EP3281640A1 (en) | 2011-06-17 | 2018-02-14 | President and Fellows of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
EP4261222A1 (en) | 2020-12-09 | 2023-10-18 | HK inno.N Corporation | ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4843841B1 (nl) * | 1969-09-06 | 1973-12-21 | ||
GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
CA1208546A (en) * | 1981-09-08 | 1986-07-29 | Anthony Cerami | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US5700466A (en) * | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
JPS58138383A (ja) † | 1982-02-13 | 1983-08-17 | Nippon Shinyaku Co Ltd | 生理活性物質の製法 |
EP0117705A3 (en) * | 1983-02-24 | 1985-09-25 | The Regents Of The University Of California | Monoclonal antibody specific for monocytes and blast cells |
JPH0780914B2 (ja) * | 1984-04-02 | 1995-08-30 | 旭化成工業株式会社 | ヒト腫瘍壊死因子に対する抗体 |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
IL75318A (en) * | 1984-05-31 | 1994-08-26 | Genentech Inc | Recombinant human memotoxin and methods for its recombinant production |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
GR851626B (nl) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
JPS61124392A (ja) * | 1984-11-22 | 1986-06-12 | Asahi Chem Ind Co Ltd | 遺伝子組換体の産生する生理活性物質の精製法 |
US4684623A (en) * | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
ES2159529T5 (es) * | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
-
1984
- 1984-12-20 IL IL73883A patent/IL73883A/xx not_active IP Right Cessation
-
1985
- 1985-12-13 DE DE200412000007 patent/DE122004000007I1/de active Pending
- 1985-12-13 DE DE198585115918T patent/DE186833T1/de active Pending
- 1985-12-13 DE DE3586536T patent/DE3586536T3/de not_active Expired - Lifetime
- 1985-12-13 EP EP85115918A patent/EP0186833B2/en not_active Expired - Lifetime
- 1985-12-13 DE DE200412000017 patent/DE122004000017I1/de active Pending
- 1985-12-13 DE DE19853586536 patent/DE122004000005I1/de active Pending
- 1985-12-18 CA CA000498017A patent/CA1337518C/en not_active Expired - Lifetime
- 1985-12-18 AU AU51424/85A patent/AU601144B2/en not_active Expired
- 1985-12-19 JP JP60286811A patent/JPS61191620A/ja active Pending
- 1985-12-20 ZA ZA859757A patent/ZA859757B/xx unknown
-
1991
- 1991-11-13 US US07/794,365 patent/US6090923A/en not_active Expired - Lifetime
-
1993
- 1993-10-27 JP JP5269155A patent/JPH0787966A/ja active Pending
-
2004
- 2004-02-12 NL NL300142C patent/NL300142I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
JPS61191620A (ja) | 1986-08-26 |
DE3586536T2 (de) | 1993-02-18 |
EP0186833A3 (en) | 1987-05-27 |
DE3586536T3 (de) | 2002-05-08 |
US6090923A (en) | 2000-07-18 |
DE122004000017I1 (de) | 2005-06-16 |
ZA859757B (en) | 1986-09-24 |
EP0186833A2 (en) | 1986-07-09 |
AU5142485A (en) | 1986-06-26 |
IL73883A0 (en) | 1985-03-31 |
DE186833T1 (de) | 1986-12-18 |
NL300142I2 (nl) | 2005-08-01 |
JPH0787966A (ja) | 1995-04-04 |
IL73883A (en) | 1990-12-23 |
DE122004000005I1 (de) | 2006-06-08 |
EP0186833B1 (en) | 1992-08-19 |
AU601144B2 (en) | 1990-09-06 |
EP0186833B2 (en) | 2001-11-28 |
DE3586536D1 (de) | 1992-09-24 |
CA1337518C (en) | 1995-11-07 |
DE122004000007I1 (de) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300142I2 (nl) | Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine. | |
DE3689734D1 (de) | Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen. | |
NL192157B (nl) | Werkwijze voor de vervaardiging van een inductantie-element. | |
NL193165B (nl) | Werkwijze voor de vervaardiging van een voor warmte geïsoleerde leidingbuis. | |
NL194832B (nl) | Werkwijze voor het vormen van een dunne-halfgeleiderfilm. | |
ATE143376T1 (de) | Gegen die beta-kette des leukozyten-adhäsions- rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung | |
DE3167698D1 (en) | Method for the determination of antigens with the aid of two or more monoclonal antibodies | |
NL186831C (nl) | Werkwijze voor het isoleren van een pijp. | |
NL191796C (nl) | Werkwijze voor het verstevigen van een slappe bodem. | |
NL186643C (nl) | Werkwijze voor het veresteren van natuurhars. | |
NL189373C (nl) | Werkwijze voor het verzegelen van een flensverbinding. | |
NL188432C (nl) | Werkwijze voor het vervaardigen van een mosfet. | |
NL7902621A (nl) | Werkwijze voor het vormen van een aftakdichting. | |
EP0198086A4 (en) | MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY. | |
NL190814B (nl) | Werkwijze voor het bereiden van een polyacetaalcopolymeer. | |
NL190453C (nl) | Werkwijze voor de versteviging van een geologische formatie. | |
NL190000C (nl) | Werkwijze voor het centreren van een ruwe edelsteen. | |
NL184576B (nl) | Werkwijze voor het bereiden van een samengesteld materiaal, bestaande uit metaalnitriden. | |
FI862978A0 (fi) | Onkofetaalisia spesifisiä monoklonaalisia vasta-aineita, menetelmä niiden valmistamiseksi ja niiden käyttö. | |
NL8403069A (nl) | Nieuwe werkwijze voor het bereiden van een cefalosporine, een tussenprodukt voor het cefalosporine en werkwijze voor het bereiden van het tussenprodukt. | |
NL186319C (nl) | Werkwijze voor het zuiveren van glucosaminoglucan. | |
WO1992004464A3 (en) | Monoclonal antibodies against tenascin | |
NL189254C (nl) | Werkwijze voor het zuiveren van indool. | |
NL186619B (nl) | Werkwijze voor het regenereren van een ijzer fosfaat-katalysator. | |
NL191009B (nl) | Sigaret en werkwijze voor het wijzigen van de omtreksvormgeving van een sigaret. |